Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Vaxcyte, Inc. (5VA.F)

26.00
+0.60
+(2.36%)
At close: 8:19:36 AM GMT+2

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Grant E. Pickering M.B.A. Co-Founder, CEO & Director 995.55k 1.05M 1968
Mr. Andrew L. Guggenhime M.B.A. President & CFO 720.29k 1.67M 1968
Mr. James Wassil M.B.A., M.S. Executive VP & COO 457.24k 828.06k 1970
Mr. Mikhail Eydelman J.D. Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary 600.78k 816.67k 1982
Dr. Jeff Fairman Ph.D. Co-Founder & VP of Research -- -- 1965
Ms. Janet Graesser Senior Vice President of Corporate Communications & Investor Relations -- -- --
Ms. Whitney Jones Chief People Officer -- -- --
Mr. Paul W. Sauer M.B.A. Senior Vice President of Process Development & Manufacturing 534.38k -- 1962
Mr. Harp Dhaliwal M.B.A. Chief Technical Operations Officer 128.54k -- 1974
Sam Iki Senior Vice President of Project Management -- -- --

Vaxcyte, Inc.

825 Industrial Road
Suite 300
San Carlos, CA 94070
United States
650 837 0111 https://vaxcyte.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
414

Description

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Corporate Governance

Vaxcyte, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 7. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 6, 2025 at 8:00 PM UTC - May 12, 2025 at 8:00 PM UTC

Vaxcyte, Inc. Earnings Date

Recent Events

Related Tickers